Trial reportInternational journal of chronic obstructive pulmonary disease2013
Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients.
Trial report in International journal of chronic obstructive pulmonary disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2019Pooled it
- Trial
- Trial
- A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.International journal of chronic obstructive pulmonary disease · 2018Trial
- Changes in ventilation-perfusion during and after an COPD exacerbation: an assessment using fluid dynamic modeling.International journal of chronic obstructive pulmonary disease · 2018Trial
- Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA.International journal of chronic obstructive pulmonary disease · 2016Trial
- Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Erdosteine, but Not N-Acetylcysteine, is Associated with Improved Homogeneity of Alveolar Ventilation in Patients with Mild-to-Moderate COPD Treated with LABA/LAMA.International journal of chronic obstructive pulmonary disease · 2026Article
- Antioxidants and Reactive Oxygen Species: Shaping Human Health and Disease Outcomes.International journal of molecular sciences · 2025Review
- Article
- Oxidative Stress Promotes Corticosteroid Insensitivity in Asthma and COPD.Antioxidants (Basel, Switzerland) · 2021Review
- Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review.Drug safety · 2021Review
- Relationship between neutrophil-lymphocyte ratio and short-term prognosis in the chronic obstructive pulmonary patients with acute exacerbation.Bioscience reports · 2019Article
- Red wine polyphenol extract efficiently protects intestinal epithelial cells from inflammationToxicology research · 2016Article
- N-acetylcysteine in COPD: why, how, and when?Multidisciplinary respiratory medicine · 2015Review
- Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.Drug design, development and therapy · 2015Article
- Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.International journal of chronic obstructive pulmonary disease · 2015Article
- Computational modeling of the obstructive lung diseases asthma and COPD.Journal of translational medicine · 2014Article
- Azithromycin use prior to ICU admission is associated with a lower short-term mortality for critically ill acute exacerbations of chronic obstructive pulmonary disease patients: A retrospective cohort study.Chronic respiratory diseaseArticle
- Lung deposition of inhaled once-daily long-acting muscarinic antagonistsTherapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have demonstrated the potential beneficial effect of N-acetylcysteine (NAC) in chronic obstructive pulmonary disease (COPD). However, the required dose and responder phenotype remain unclear. The current study investigated the effect of high-dose NAC on airway geometry, inflammation, and oxidative stress in COPD patients. Novel functional respiratory imaging methods combining multislice computed tomography images and computer-based flow simulations were used with high sensitivity for detecting changes induced by the therapy.
methodsTwelve patients with Global Initiative for Chronic Obstructive Lung Disease stage II COPD were randomized to receive NAC 1800 mg or placebo daily for 3 months and were then crossed over to the alternative treatment for a further 3 months.
resultsSignificant correlations were found between image-based resistance values and glutathione levels after treatment with NAC (P = 0.011) and glutathione peroxidase at baseline (P = 0.036). Image-based resistance values appeared to be a good predictor for glutathione peroxidase levels after NAC (P = 0.02), changes in glutathione peroxidase levels (P = 0.035), and reduction in lobar functional residual capacity levels (P = 0.00084). In the limited set of responders to NAC therapy, the changes in airway resistance were in the same order as changes induced by budesonide/formoterol.
conclusionA combination of glutathione, glutathione peroxidase, and imaging parameters could potentially be used to phenotype COPD patients who would benefit from addition of NAC to their current therapy. The findings of this small pilot study need to be confirmed in a larger pivotal trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.